• SPX
  • $5,996.98
  • 0.4 %
  • $23.88
  • DJI
  • $43,988.99
  • 0.59 %
  • $259.65
  • N225
  • $39,500.37
  • 0.3 %
  • $118.96
  • FTSE
  • $8,072.39
  • -0.84 %
  • -$68.35
  • IXIC
  • $19,288.33
  • 0.1 %
  • $18.87
iBio, Inc. (IBIO) Stock Price, News & Analysis

iBio, Inc. (IBIO) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.59

$0.05

(1.97%)

Day's range
$2.45
Day's range
$2.63
50-day range
$1.74
Day's range
$3.15
  • Country: US
  • ISIN: US4510337086
52 wk range
$1.02
Day's range
$6.2
  • CEO: Dr. Martin B. Brenner D.V.M., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -14.78
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (IBIO)
  • Company iBio, Inc.
  • Price $2.59
  • Changes Percentage (1.97%)
  • Change $0.05
  • Day Low $2.45
  • Day High $2.63
  • Year High $6.20

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $3.60
  • High Stock Price Target $3.60
  • Low Stock Price Target $3.60
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$7.23
  • Trailing P/E Ratio -0.33
  • Forward P/E Ratio -0.33
  • P/E Growth -0.33
  • Net Income $-24,907,000

Income Statement

Quarterly

Annual

Latest News of IBIO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.